GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Return-on-Tangible-Asset

CRGX (Cargo Therapeutics) Return-on-Tangible-Asset : -87.11% (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cargo Therapeutics's annualized Net Income for the quarter that ended in Mar. 2025 was $-337.99 Mil. Cargo Therapeutics's average total tangible assets for the quarter that ended in Mar. 2025 was $388.01 Mil. Therefore, Cargo Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -87.11%.

The historical rank and industry rank for Cargo Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

CRGX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -555.38   Med: -86.13   Max: -38.64
Current: -50.53

During the past 4 years, Cargo Therapeutics's highest Return-on-Tangible-Asset was -38.64%. The lowest was -555.38%. And the median was -86.13%.

CRGX's Return-on-Tangible-Asset is ranked worse than
60.04% of 1499 companies
in the Biotechnology industry
Industry Median: -36.14 vs CRGX: -50.53

Cargo Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Cargo Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Return-on-Tangible-Asset Chart

Cargo Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-129.88 -555.38 -42.37 -38.64

Cargo Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.72 -38.88 -35.63 -42.02 -87.11

Competitive Comparison of Cargo Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Cargo Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cargo Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's Return-on-Tangible-Asset falls into.


;
;

Cargo Therapeutics Return-on-Tangible-Asset Calculation

Cargo Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-167.502/( (453.036+414.054)/ 2 )
=-167.502/433.545
=-38.64 %

Cargo Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-337.992/( (414.054+361.957)/ 2 )
=-337.992/388.0055
=-87.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Cargo Therapeutics  (NAS:CRGX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Cargo Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cargo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.